SLGL
Sol-Gel Technologies Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$69.52
−0.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.8M | 19.4M | 11.5M | 1.6M | 3.9M |
| Cost of Revenue | — | — | — | — | 12.7M |
| Gross Profit | 1.8M | 19.4M | 11.5M | 1.6M | (8.8M) |
| Operating Expenses | |||||
| R&D Expense | 15.8M | 22.8M | 17.8M | 23.5M | 12.7M |
| SG&A Expense | 3.7M | 4.2M | 5.7M | 7.4M | 7.4M |
| General & Admin Expense | 2.7M | 4.2M | 5.7M | 7.4M | 7.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (54.0K) | (54.0K) | — | (55.0K) | (12.7M) |
| Total Operating Expenses | 19.5M | 26.9M | 23.6M | 30.9M | 7.4M |
| Cost and Expenses | 19.5M | 26.9M | 23.6M | 30.9M | 20.1M |
| Operating Income (EBIT) | (17.7M) | (7.5M) | (12.0M) | (29.3M) | (16.2M) |
| Non-Operating | |||||
| Interest Income | 1.4M | 1.4M | 1.4M | 2.1M | 1.3M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 1.4M | 1.4M | 1.4M | 2.1M | 1.3M |
| Other Non-Op Income/Expense | 1.4M | 1.4M | 1.4M | 2.1M | 1.3M |
| Non-Operating Income (excl Interest) | (346.0K) | — | — | — | — |
| EBT (Pre-Tax Income) | (16.3M) | (6.1M) | (10.6M) | (27.2M) | (14.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (16.3M) | (6.1M) | (10.6M) | (27.2M) | (14.9M) |
| Earnings from Cont. Ops | (16.3M) | (6.1M) | (10.6M) | (27.2M) | (14.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (16.3M) | (6.1M) | (10.6M) | (27.2M) | (14.9M) |
| Per Share | |||||
| Basic EPS | ($5.64) | ($2.20) | ($3.79) | ($10.01) | ($0.65) |
| Diluted EPS | ($5.64) | ($2.20) | ($3.79) | ($10.01) | ($0.65) |
| Revenue Per Share | $0.55 | $6.96 | $4.14 | $0.57 | $0.17 |
| Shares | |||||
| Basic Shares Outstanding | 3.3M | 2.8M | 2.8M | 2.7M | 23.1M |
| Diluted Shares Outstanding | 3.3M | 2.8M | 2.8M | 2.7M | 23.1M |
| Profitability Metrics | |||||
| EBITDA | (17.4M) | (7.4M) | (11.8M) | (29.0M) | (15.7M) |
| D&A | — | 109.0K | 233.0K | 342.0K | 562.0K |
| EBIT | (17.4M) | (7.5M) | (12.0M) | (29.3M) | (16.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026